OR WAIT null SECS
March 24, 2023
Harm Reduction Therapeutics and Catalent have signed a commercial supply agreement for naloxone nasal spray to reverse opioid overdoses.
A new Interagency Working Group for Bayh-Dole will review the government’s authority to revoke licenses for medical products.
March 23, 2023
The recent document will guide the use of DHT-derived data in regulatory decision-making for drugs and biological products.
Three new awards have been added to the roster for 2023 and include some specific highlights that have occurred over the past few years.
March 22, 2023
The decision was based on results from the PROpel Phase III trial.
This approval makes the drug the first and only targeted medicine indicated to treat this population of children in Europe and the United States.
March 21, 2023
Sanofi intends to cut its US list price for Lantus (insulin glargine injection) by 78% and cap out-of-pocket costs at $35 for all patients with commercial insurance.
Additionally, the MSG discussed plans to mitigate shortages of antibiotics for the next autumn and winter season.
March 17, 2023
Evotec and Bristol Myers Squibb have announced progress in their strategic protein degradation partnership.
Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs utilizing the PEDAL platform.